$PHG

Royal Philips (NYSE: PHG, AEX: PHIA) said it is expanding its open patient monitoring ecosystem via collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare. The partners add wearable and out-of-hospital monitoring options integrated with Philips platforms such as the Patient Information Center (PIC) iX and Philips Mobile Cardiac Telemetry.

Royal Philips (NYSE: PHG) said it is expanding its open patient monitoring ecosystem with collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare. Philips said the partners’ wearables and out-of-hospital platforms integrate with Philips systems to support continuous near real-time monitoring of multiple vital signs, plus Philips Mobile Cardiac Telemetry for up to 30 days post-discharge.

UBS downgraded Koninklijke Philips N.V. (PHG) to neutral from buy and cut its price target to €24 from €32.50, citing China pricing pressure and inflation that may delay margin improvement and a return to organic growth above 5%. UBS forecasts weaker organic growth and lowered 2027+ adjusted EPS, though it raised 2026 EPS on a tariff refund.

Philips reported Q2 sales of €4.4B (up 4% comparable) and an adjusted EBITA margin of 16.4%. The company said a €186M US tariff refund drove most of the margin improvement, while underlying margin fell. Orders were down 1% comparable, with some North America Connected Care contracts delayed. Full-year sales guidance was unchanged; margin and free cash flow guidance were raised.

Analyst estimates for Koninklijke Philips N.V. NY Registry Shares show the average 12-month price target was cut from $31.34 to $31.15, with a range of $26.64 to $37.57, according to 18 analysts. Based on the Jul. 28 close, the target suggests about 22% upside. The consensus rating remains “Buy” (10 Buys, 11 Holds, 0 Sells) from 21 analysts.

Analyst estimates cited by FactSet show Koninklijke Philips N.V. NY Registry Shares’ average 12-month price target was cut to $31.6 from $31.78. The new range is $25.73 to $37.57, implying about 26% upside versus the Jul. 27 close. Consensus remains “Buy” with 10 Buys, 11 Holds, and 0 Sells.

Philips (PHG) shares fell about 9% in European trading after the company reported weaker-than-expected orders and warned that conditions in China are getting harder. Philips said comparable order intake fell 1% mainly due to delays in closing large U.S. contracts. It kept an improved full-year profitability outlook but expects third-quarter adjusted EBITDA margin below last year.

Philips CEO Roy Jakobs discussed the company’s half-year results, saying costs for chips, plastics and transportation face pressure. He also commented on demand conditions for semiconductors and on China. The interview was published by CNBC’s Squawk Box Europe and references Philips (PHG).

Koninklijke Philips N.V. shares fell after the company reported weak Q2 order intake despite profit growth. Philips said US tariff refunds boosted results and raised its FY2026 comparable sales outlook to 3% to 4.5%, adjusted EBITA margin to 13.5% to 14.0% (about 1% from refunds), and free cash flow to €1.5-€1.7B. Q2 net income rose to €386M.

European stocks rose modestly as strong earnings from Unilever, LVMH, Orange, Mercedes-Benz, BMW, Volkswagen and Safran offset inflation and Fed/ECB rate concerns. STOXX 600 gained 0.2%, DAX 0.2%, CAC 40 0.5%, FTSE 100 flat. Unilever jumped 6% on Q2 underlying sales above forecasts; Philips fell 8.5% despite better core earnings.